KLKP1: A Potential Drug Target and Biomarker (G606293)

Target Name: KLKP1

NCBI ID: G606293

KLKP1

KLKP1: A Potential Drug Target and Biomarker

KLKP1, also known as KARMA, is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. It is a part of the KLK gene family, which encodes for a family of cytoplasmic proteins involved in various cellular processes, including intracellular signaling, cell adhesion, and tissue repair. One of the KLKP genes, KLKP1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The KLKP1 protein is composed of 191 amino acid residues and has a calculated molecular weight of 21.9 kDa. It is expressed in a variety of tissues, including the brain, where it is predominantly expressed in the peri-synaptic terminal of neurons and glial cells. KLKP1 is also expressed in other tissues, including the lungs, heart, kidneys, and gastrointestinal tract, where it is primarily expressed in epithelial cells.

KLKP1 functions as a cytoplasmic protein that is involved in various cellular processes, including intracellular signaling, cell adhesion, and tissue repair. It is a member of the KLK gene family, which encodes for a family of cytoplasmic proteins involved in intracellular signaling, including the TCF/TAZ signaling pathway. The TCF/TAZ signaling pathway is a critical pathway that regulates cell proliferation, differentiation, and survival, and is involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

KLKP1 has been shown to be involved in several cellular processes that are important for disease development and progression. For example, KLKP1 has been shown to be involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs. KLKP1 has been shown to be involved in the regulation of cell survival, as it has been shown to play a role in the regulation of apoptosis, which is a critical mechanism that helps cells eliminate themselves when they are no longer needed.

In addition to its role in cellular processes, KLKP1 has also been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KLKP1 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Given its involvement in various cellular processes and its potential role in disease development and progression, KLKP1 has become a focus of research for the development of new treatments for a variety of diseases. Several studies have shown that KLKP1 can be a drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In the context of cancer, KLKP1 has been shown to be involved in the regulation of cell adhesion and survival, which are critical for the development and progression of cancer. Several studies have shown that KLKP1 can be a potential drug target for cancer, and several researchers have investigated the potential clinical applications of KLKP1 inhibitors. For example, one study reported that inhibiting KLKP1 using a small molecule inhibitor improved the sensitivity of cancer cells to chemotherapy, suggesting that KLKP1 may be a promising target for cancer treatment.

In the context of neurodegenerative diseases, KLKP1 has

Protein Name: Kallikrein Pseudogene 1

The "KLKP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLKP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets